Fetal Pharmacology and Therapeutics Workshop
The U.S. Food and Drug Administration (FDA) in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) will host a two-day virtual public workshop entitled “Fetal Pharmacology and Therapeutics” on October 21-22, 2021 to discuss the current state of fetal pharmacology and therapeutics and how it pertains to pediatric drug development.
Thu, Oct 21 10:00 AM – 3:15 PM ET
Fri, Oct 22 10:00 AM – 2:00 PM ET
Fetal pharmacology has made significant advances in recent years and has moved into the “clinical science” space with considerations for both fetal therapeutics allowing in-utero treatment of the fetus to avert postnatal disease as well as aversion of fetal toxicity from in-utero exposure to drugs following medications administered to the pregnant woman. This advance in knowledge requires addressing both the regulatory and scientific aspects of fetal pharmacology.
Review general regulatory and ethical considerations for fetal pharmacology and therapeutics
Describe methods to assess clinical and nonclinical safety and efficacy assessments to support clinical trials of drugs in pregnancy and the fetus
Highlight advances and existing knowledge in fetal therapeutics
Discuss key aspects of maternal-fetal modeling and simulation
You may register for remote access. This workshop is intended for clinicians, academicians, drug developers, and regulators.
This virtual public workshop will be available to view via webcast, but pre-registration is still required. You will receive the link to access the live webinar several weeks prior to the meeting. You must log in with your username and password which you create when you register.
This workshop is supported by the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award U01FD005946 totaling $5,000 with 100 percent funded by FDA/HHS. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by FDA/HHS, or the U.S. Government.
If you have any additional questions about this workshop, please contact:
Gilbert Burckart, PharmD.
U.S. Food and Drug Administration
10903 New Hampshire Avenue
Silver Spring, MD 20993